Ardelyx

Ardelyx Debt

The Debt of Ardelyx (ARDX) as of Nov 5, 2026 is 202.83 M USD. In the previous year, Debt was 150.85 M USD — a change of 34.46% (higher).

Debt

202.83 MUSD

YoY

34.46%

Last updated:

In 2025, Ardelyx's total debt was 202.83 M USD, a 34.46% change from the 150.85 M USD total debt recorded in the previous year.

The Ardelyx Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2018
49.20 M USD
Jan 1, 2019
50.00 M USD
Jan 1, 2020
50.80 M USD
Jan 1, 2021
32.30 M USD
Jan 1, 2022
26.70 M USD
Jan 1, 2023
49.82 M USD
Jan 1, 2024
150.85 M USD
Jan 1, 2025
202.83 M USD
The Ardelyx Debt history
YEARDebtYoY
202.83 MUSD+34.46%
150.85 MUSD+202.78%
49.82 MUSD+86.60%
26.70 MUSD-17.34%
32.30 MUSD-36.42%
50.80 MUSD+1.60%
50.00 MUSD+1.63%
49.20 MUSD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Ardelyx Stock analysis

What does Ardelyx do? Ardelyx Inc. is a biotechnology company founded in 2007 by researchers to develop life-changing medications. The company is based in Fremont, California, USA and focuses on researching kidney and gastrointestinal diseases, as well as cardiology and metabolic disorders. Its business model is based on identifying unmet medical needs and developing drugs to meet those needs. Ardelyx works closely with patients to understand their medical problems and develop specific solutions. The company categorizes its products into three categories: kidney, gastrointestinal, and cardiology/metabolism. Ardelyx has developed a medication called Tenapanor for chronic kidney disease, which reduces phosphorus levels in the blood, lowering the risk of cardiovascular disease. For gastrointestinal diseases like irritable bowel syndrome and ulcerative colitis, Ardelyx has developed Tenapanor to reduce pain and discomfort by regulating fluid and nutrient volumes in the intestine. In the field of cardiology/metabolic disorders, Ardelyx is working on developing medications to regulate cholesterol levels and the lipid metabolism system, which can be the cause of heart disease or diabetes. The company is awaiting approval for Ibsrela, a medication for chronic constipation and pelvic floor disorders, as well as RDX013, a medication to regulate lipid metabolism. Ardelyx also benefits from collaborating with other pharmaceutical companies, such as AstraZeneca, which has supported the development of novel treatments for kidney diseases. The partnership with AstraZeneca focuses on creating treatments that prevent damage to kidney cells or the cardiovascular system. Ardelyx has also received a number of awards and recognition, demonstrating its effectiveness and performance in the biotechnology industry. For example, in 2019, Inc. Magazine included Ardelyx for the fourth consecutive year in its list of the "5000 fastest-growing private companies in the USA." This publication highlighted Ardelyx's tripling of its employee count during the same period. Overall, Ardelyx focuses on researching and developing innovative medications that meet the needs of patients with kidney, gastrointestinal, cardiology, and metabolic disorders. Despite being a young company, it already produces a range of innovative products and is committed to developing life-changing medications through its research and improving the quality of life for affected patients. Output: Ardelyx Inc. is a biotechnology company focused on developing life-changing medications for kidney, gastrointestinal, cardiology, and metabolic disorders. They collaborate with patients to understand their medical problems and develop specific solutions. They have developed medications such as Tenapanor for chronic kidney disease and gastrointestinal diseases. They are awaiting approval for medications to treat chronic constipation and pelvic floor disorders, as well as regulate lipid metabolism. Ardelyx has partnerships with other pharmaceutical companies like AstraZeneca. They have received awards for their effectiveness and performance in the biotechnology industry. Ardelyx is one of the most popular companies on Eulerpool.

Debt Details

Understanding Ardelyx's Debt Structure

Ardelyx's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Ardelyx's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Ardelyx’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Ardelyx’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Ardelyx stock

Debt of Ardelyx is 202.83 M USD in 2025.

Debt of Ardelyx changed from 150.85 M USD to 202.83 M USD, representing a 34.46% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt Ardelyx since 2006 – with annual values, charts, and detailed analysis.

Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Ardelyx historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Ardelyx

All Key Metrics — Ardelyx